Side-by-side comparison of AI visibility scores, market position, and capabilities
Fremont CA semiconductor etch and deposition (NASDAQ: LRCX) $14.9B FY2024 revenue; 3D NAND/HBM etch leader, 40%+ plasma etch share, $5B+ services revenue competing with Applied Materials and Tokyo Electron.
Lam Research Corporation is a Fremont, California-based semiconductor equipment company — publicly traded on the NASDAQ (NASDAQ: LRCX) as an S&P 500 Information Technology component — designing and manufacturing etch and deposition systems critical for semiconductor chip fabrication, providing products across plasma etch (removing material layers with precision), chemical vapor deposition (CVD — depositing thin films on wafers), atomic layer deposition (ALD — depositing single atomic layers with Angstrom-level precision), and related services through approximately 17,000 employees worldwide. In fiscal year 2024 (ending June 2024), Lam Research reported revenues of $14.9 billion, with strong revenue recovery driven by semiconductor industry capex expansion (NAND flash memory producers resuming equipment orders after the 2022-2023 memory market downturn, and DRAM producers expanding capacity for HBM — High Bandwidth Memory — required in NVIDIA AI GPU packages). CEO Tim Archer has positioned Lam Research as an "advanced process technology" partner rather than a pure equipment vendor: Lam's ALD-Select, VECTOR deposition, and Kiyo etch systems are co-developed with leading chipmakers (TSMC, Samsung, SK Hynix, Micron) for specific process nodes — creating application-specific systems optimized for 3nm logic, 1-alpha DRAM, and 200+ layer 3D NAND that require Lam's process understanding rather than generic equipment. Lam Research's Global Customer Support (GCS) organization provides equipment maintenance, spare parts, and process consulting services — generating $5+ billion annually in recurring service revenue that is less cyclical than equipment capital expenditure.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.